NCT02247310View on ClinicalTrials.gov

BETAEVAL Global - The New BETACONNECT Auto-injector : Adherence and EVALuation of Multiple Sclerosis Patients Treated With Betaferon

CompletedOBSERVATIONAL
Enrollment

498

Participants

Timeline

Start Date

October 20, 2014

Primary Completion Date

July 19, 2016

Study Completion Date

November 8, 2016

Conditions
Multiple Sclerosis, Relapsing Remitting
Interventions
DRUG

Interferon beta-1b (Betaferon®, BAY 86-5046)

Patients will be treated with Betaferon

DEVICE

BETACONNECT

Auto-injector device to support the injection of Betaferon

Trial Locations (11)

Unknown

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY

NCT02247310 - BETAEVAL Global - The New BETACONNECT Auto-injector : Adherence and EVALuation of Multiple Sclerosis Patients Treated With Betaferon | Biotech Hunter | Biotech Hunter